Can EPIC Be a Low-Cost Alternative to HIPEC in Advanced Epithelial Ovarian Cancer in Resource-Constraint Settings? Experience from Tertiary Care Oncology Center-Reference-Cited by-同舟云学术

Can EPIC Be a Low-Cost Alternative to HIPEC in Advanced Epithelial Ovarian Cancer in Resource-Constraint Settings? Experience from Tertiary Care Oncology Center

Published:2023-05-30 Issue:S1 Volume:14 Page:250-256
ISSN:0975-7651
Container-title:Indian Journal of Surgical Oncology
language:en
Short-container-title:Indian J Surg Oncol

Author:

Talluri Sri Harsha,Ray M.D.^ORCID,N Premanand,Kumar Lalit,Garg Rakesh,Deo SVS

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

https://link.springer.com/content/pdf/10.1007/s13193-023-01743-7.pdf

Reference12 articles.

1. Murthy NS, Shalini S, Suman G, Pruthvish S, Mathew A (2009) Changing trends in incidence of ovarian cancer—the Indian scenario. Asian Pac J Cancer Prev 10(6):1025–1030

2. Impact of prehabilitation during neoadjuvant chemotherapy and interval cytoreductive surgery on ovarian cancer patients: a pilot study | World Journal of Surgical Oncology | Full Text [Internet]. [cited 2022 Sep 13]. Available from: https://wjso.biomedcentral.com/articles/10.1186/s12957-022-02517-1

3. Dholakia J, Cohn DE, Straughn JM, Dilley SE (2021) Prehabilitation for medically frail patients undergoing surgery for epithelial ovarian cancer: a cost-effectiveness analysis. J Gynecol Oncol 32(6):e92

4. Ray MD, Deo SSV, Kumar L, Gaur MK (2021) Upfront cytoreductive surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer in Indian patients. Future Oncol 17(27):3607–3614

5. Henderson JT, Webber EM, Sawaya GF (2018) Screening for ovarian cancer: updated Evidence report and systematic review for the US Preventive Services Task Force. JAMA 319(6):595–606